Quantitative in vivo neurochemical profiling in humans: Where are we now?

International Journal of Epidemiology

Volumn 45, Issue 5, 2016, Pages 1339-1350

  McKay, Jessica ^a   Tkáč, Ivan ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

1H MRS; CNS disorders; Methodology; Neurochemical profiling; Spectral quality

Indexed keywords

BIOLOGICAL MARKER;

BLOOD; BRAIN; EPIDEMIOLOGY; METABOLITE; METHODOLOGY; NERVOUS SYSTEM DISORDER; NEUROLOGY; NUCLEAR MAGNETIC RESONANCE; PHENOTYPE; PUBLIC HEALTH; SPECTRAL ANALYSIS;

BLOOD BRAIN BARRIER; HUMAN; IN VIVO STUDY; NEUROCHEMISTRY; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE SCANNER; PHENOTYPE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; REVIEW; BLOOD; BRAIN; METABOLISM;

BIOMARKERS; BRAIN; HUMANS; NERVOUS SYSTEM DISEASES; NEUROCHEMISTRY; PROTON MAGNETIC RESONANCE SPECTROSCOPY;

EID: 85019181350     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyw235     Document Type: Review

References (66)

1. Bictash M, Ebbels TM, Chan Q et al. Opening up the 'Black Box': metabolic phenotyping and metabolome-wide association studies in epidemiology. J Clin Epidemiol 2010;63:970-9.
2. Soininen P, Kangas AJ, Wurtz P, Suna T, Ala-Korpela M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circulation Cardiovascular Genetics 2015;8:192-206.
3. Holmes E, Wilson ID, Nicholson JK. Metabolic phenotyping in health and disease. Cell 2008;134:714-17.
4. Kinross J, Li JV, Muirhead LJ, Nicholson J. Nutritional modulation of the metabonome: applications of metabolic phenotyping in translational nutritional research. Current Opinion in Gastroenterology 2014;30:196-207.
5. Kujala UM, Makinen VP, Heinonen I et al. Long-term leisuretime physical activity and serum metabolome. Circulation 2013;127:340-8.
6. Faber JH, Malmodin D, Toft H et al. Metabonomics in diabetes research. Journal of Diabetes Science and Technology 2007;1:549-57.
7. Makinen VP, Kangas AJ, Soininen P, Wurtz P, Groop PH, Ala-Korpela M. Metabolic phenotyping of diabetic nephropathy. Clin Pharmacol Ther 2013;94:566-9.
8. Louis E, Adriaensens P, GuedensWet al. Metabolic phenotyping of human blood plasma: a powerful tool to discriminate between cancer types? Ann Oncol 2016;27:178-84.
9. Xia J, Broadhurst DI, Wilson M, Wishart DS. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics: Official Journal of the Metabolomic Society 2013;9:280-99.
10. Everett JR. Pharmacometabonomics in humans: a new tool for personalized medicine. Pharmacogenomics 2015;16:737-54.
11. Lindon JC, Nicholson JK. The emergent role of metabolic phenotyping in dynamic patient stratification. Expert Opinion on Drug Metabolism and Toxicology 2014;10:915-19.
12. Nicholson JK. Global systems biology, personalized medicine and molecular epidemiology. Molecular Systems Biology 2006;2:52.
13. Dumas ME, Davidovic L. Metabolic profiling and phenotyping of central nervous system diseases: metabolites bring insights into brain dysfunctions. Journal of Neuroimmune Pharmacology: The Official Journal of the Society on NeuroImmune Pharmacology 2015;10:402-24.
14. Jove M, Portero-Otin M, Naudi A, Ferrer I, Pamplona R. Metabolomics of human brain aging and age-related neurodegenerative diseases. Journal of Neuropathology and Experimental Neurology 2014;73:640-57.
15. Tukiainen T, Tynkkynen T, Makinen VP et al. A multimetabolite analysis of serum by 1H NMR spectroscopy: early systemic signs of Alzheimer's disease. Biochem Biophys Res Commun 2008;375:356-61.
16. An M, Gao Y. Urinary biomarkers of brain diseases. Genomics, Proteomics and Bioinformatics 2015;13:345-54.
17. Czech C, Berndt P, Busch K et al. Metabolite profiling of Alzheimer's disease cerebrospinal fluid. PloS One 2012;7:e31501.
18. Ohman A, Forsgren L. NMR metabonomics of cerebrospinal fluid distinguishes between Parkinson's disease and controls. Neurosci Lett 2015;594:36-9.
19. Trushina E, Mielke MM. Recent advances in the application of metabolomics to Alzheimer's Disease. Biochim Biophys Acta 2014;1842:1232-9.
20. Tsang TM, Woodman B, McLoughlin GA et al. Metabolic characterization of the R6/2 transgenic mouse model of Huntington's disease by high-resolution MAS 1H NMR spectroscopy. J Proteome Res 2006;5:483-92.
21. Deelchand DK, Adanyeguh IM, Emir UE et al. Two-site reproducibility of cerebellar and brainstem neurochemical profiles with short-echo, single-voxel MRS at 3T. Magn Reson Med 2015;73:1718-25.
22. Emir UE, Auerbach EJ, Van DeMoortele PF et al. Regional neurochemical profiles in the human brain measured by (1)H MRS at 7 T using local B(1) shimming. NMR Biomed 2012;25:152-60.
23. Mekle R, Mlynarik V, Gambarota G, Hergt M, Krueger G, Gruetter R. MR spectroscopy of the human brain with enhanced signal intensity at ultrashort echo times on a clinical platform at 3T and 7T. Magn Reson Med 2009;61:1279-85.
24. Pfeuffer J, Tkac I, Provencher SW, Gruetter R. Toward an in vivo neurochemical profile: quantification of 18 metabolites in short-echo-time (1)H NMR spectra of the rat brain. J Magn Reson 1999;141:104-20.
25. Tkac I, Gruetter R. Methodology of H NMR spectroscopy of the human brain at very high magnetic fields. Appl Magn Reson 2005;29:139-57.
26. Tkac I, Oz G, Adriany G, Ugurbil K, Gruetter R. In vivo 1H NMR spectroscopy of the human brain at high magnetic fields: metabolite quantification at 4T vs. 7T. Magn Reson Med 2009;62:868-79.
27. van de Bank BL, Emir UE, Boer VO et al. Multi-center reproducibility of neurochemical profiles in the human brain at 7 T. NMR Biomed 2015;28:306-16.
28. Beckonert O, Keun HC, Ebbels TM et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nature Protocols 2007;2:2692-703.
29. Gruetter R. Automatic, localized in vivo adjustment of all firstand second-order shim coils. Magn Reson Med 1993;29:804-11.
30. Gruetter R, Tkac I. Field mapping without reference scan using asymmetric echo-planar techniques. Magn Reson Med 2000;43:319-23.
31. Garwood M, DelaBarre L. The return of the frequency sweep: designing adiabatic pulses for contemporary NMR. J Magn Reson 2001;153:155-77.
32. Mlynarik V, Gambarota G, Frenkel H, Gruetter R. Localized short-echo-time proton MR spectroscopy with full signalintensity acquisition. Magn Reson Med 2006;56:965-70.
33. Oz G, Tkac I. Short-echo, single-shot, full-intensity proton magnetic resonance spectroscopy for neurochemical profiling at 4 T: validation in the cerebellum and brainstem. Magn Reson Med 2011;65:901-10.
34. Tkac I, Starcuk Z, Choi IY, Gruetter R. In vivo 1H NMR spectroscopy of rat brain at 1ms echo time. Magn Reson Med 1999;41:649-56.
35. Deelchand DK, Van de Moortele PF, Adriany G et al. In vivo 1H NMR spectroscopy of the human brain at 9.4 T: initial results. J Magn Reson 2010;206:74-80.
36. Tkac I, Andersen P, Adriany G, Merkle H, Ugurbil K, Gruetter R. In vivo 1H NMR spectroscopy of the human brain at 7 T. Magn Reson Med 2001;46:451-6.
37. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed 2000;13:129-53.
38. Naressi A, Couturier C, Castang I, de Beer R, Graveron-Demilly D. Java-based graphical user interface for MRUI, a software package for quantitation of in vivo/medical magnetic resonance spectroscopy signals. Comput Biol Med 2001;31:269-86.
39. Ratiney H, Sdika M, Coenradie Y, Cavassila S, van Ormondt D, Graveron-Demilly D. Time-domain semi-parametric estimation based on a metabolite basis set. NMR Biomed 2005;18:1-13.
40. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672-9.
41. Adany P, Choi IY, Lee P. B0-adjusted and sensitivity-encoded spectral localization by imaging (BASE-SLIM) in the human brain in vivo. NeuroImage 2016;134:355-64.
42. ZacharoffL, Tkac I, Song Q et al. Cortical metabolites as biomarkers in the R6/2 model of Huntington's disease. J Cereb Blood Flow Metab 2012;32:502-14.
43. Marjanska M, Auerbach EJ, Valabregue R, Van de Moortele PF, Adriany G, Garwood M. Localized 1H NMR spectroscopy in different regions of human brain in vivo at 7 T: T2 relaxation times and concentrations of cerebral metabolites. NMR Biomed 2012;25:332-9.
44. Xin L, Schaller B, Mlynarik V, Lu H, Gruetter R. Proton T1 relaxation times of metabolites in human occipital white and gray matter at 7 T. Magn Reson Med 2013;69:931-6.
45. Bednarik P, Tkac I, Giove F et al. Neurochemical and BOLD responses during neuronal activation measured in the human visual cortex at 7 Tesla. J CerebBlood FlowMetab 2015;35:601-10.
46. Lin Y, Stephenson MC, Xin L, Napolitano A, Morris PG. Investigating the metabolic changes due to visual stimulation using functional proton magnetic resonance spectroscopy at 7 T. J Cereb Blood Flow Metab 2012;32:1484-95.
47. Mangia S, Tkac I, Gruetter R, Van de Moortele PF, Maraviglia B, Ugurbil K. Sustained neuronal activation raises oxidative metabolism to a new steady-state level: evidence from 1H NMR spectroscopy in the human visual cortex. J Cereb Blood Flow Metab 2007;27:1055-63.
48. Schaller B, Mekle R, Xin L, Kunz N, Gruetter R. Net increase of lactate and glutamate concentration in activated human visual cortex detected with magnetic resonance spectroscopy at 7 tesla. J Neurosci Res 2013;91:1076-83.
49. Schaller B, Xin L, O'Brien K, Magill AW, Gruetter R. Are glutamate and lactate increases ubiquitous to physiological activation? A (1)H functional MR spectroscopy study during motor activation in human brain at 7Tesla. NeuroImage 2014;93:138-45.
50. Bednarik P, Moheet A, Deelchand DK et al. Feasibility and reproducibility of neurochemical profile quantification in the human hippocampus at 3 T. NMR Biomed 2015;28:685-93.
51. Gao F, Barker PB. Various MRS application tools for Alzheimer disease and mild cognitive impairment. AJNR Am J Neuroradiol 2014;35(Suppl 6):S4-11.
52. Zhang N, Song X, Bartha R et al. Advances in high-field magnetic resonance spectroscopy in Alzheimer's disease. Current Alzheimer Research 2014;11:367-88.
53. Kantarci K. Magnetic resonance spectroscopy in common dementias. Neuroimaging Clin N Am 2013;23:393-406.
54. Maddock RJ, Buonocore MH. MR spectroscopic studies of the brain in psychiatric disorders. Current Topics in Behavioral Neurosciences 2012;11:199-251.
55. Baruth JM, Wall CA, Patterson MC, Port JD. Proton magnetic resonance spectroscopy as a probe into the pathophysiology of autism spectrum disorders (ASD): a review. Autism Research: Official Journal of the International Society for Autism Research 2013;6:119-33.
56. MeyerhoffDJ. Brain proton magnetic resonance spectroscopy of alcohol use disorders. Handbook of Clinical Neurology 2014;125:313-37.
57. Oz G, Alger JR, Barker PB et al. Clinical protonMR spectroscopy in central nervous systemdisorders. Radiology 2014;270:658-79.
58. Adanyeguh IM, Henry PG, Nguyen TM et al. In vivo neurometabolic profiling in patients with spinocerebellar ataxia types 1, 2, 3, and 7. Mov Disord 2015;30:662-70.
59. Iltis I, Hutter D, Bushara KO et al. (1)H MR spectroscopy in Friedreich's ataxia and ataxia with oculomotor apraxia type 2. Brain Res 2010;1358:200-10.
60. Oz G, Hutter D, Tkac I et al. Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status. Mov Disord 2010;25:1253-61.
61. Oz G, Iltis I, Hutter D, Thomas W, Bushara KO, Gomez CM. Distinct neurochemical profiles of spinocerebellar ataxias 1, 2, 6, and cerebellar multiple system atrophy. Cerebellum 2011;10:208-17.
62. Mangia S, Kumar AF, Moheet AA et al. Neurochemical profile of patients with type 1 diabetes measured by (1)H-MRS at 4 T. J Cereb Blood Flow Metab 2013;33:754-9.
63. Oz G, Tkac I, Charnas LR et al. Assessment of adrenoleukodystrophy lesions by high field MRS in non-sedated pediatric patients. Neurology 2005;64:434-41.
64. Dou W, Speck O, Benner T et al. Automatic voxel positioning for MRS at 7 T. MAGMA 2015;28:259-70.
65. Lecocq A, Le Fur Y, Maudsley AA et al. Whole-brain quantitative mapping of metabolites using short echo three-dimensional proton MRSI. J Magn Reson Imaging 2015;42:280-9.
66. Posse S, Otazo R, Dager SR, Alger J. MR spectroscopic imaging: principles and recent advances. J Magn Reson Imaging 2013;37:1301-25.